

7th International Conference on Gynecology and Obstetrics

Gynecology & Obstetrics Volume: 11

September 08-09, 2021 | Paris, France

The management of advanced ovarian cancer : latest surgical developements

Hooman Soleymani majd

Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom

The ovarian cancer, also known as "silent killer", has remained the most lethal gynaecological malignancy. The single independent risk factor linked with improved survival is maximum cytoreductive effort resulting in no macroscopic residual disease. This could be gained through ultra-radical surgery which demands tackling significant tumour burden in pelvis, lower and upper abdomen which usually constitutes bowel resection, liver mobilization, ancillary cholecystectomy, extensive peritonectomy, diaphragmatic resection, splenectomy, resection of enlarged pelvic, paraaortic, and rarely cardio-phrenic lymph nodes in order to achieve optimal debulking. The above can be achieved through a holistic approach to patient's care, meticulous patient selection, and full engagement of the family. The decision needs to be carefully balanced after obtaining an informed consent, and an appreciation of the impact of such surgery on the quality of life against the survival benefit. This lecture will describe the complexity and surgical challenges in the management of advanced ovarian cancer.

Key Words:

ovarian cancer, stage III and IV, cytoreductive surgery, ultraradical surgery, residual disease, holistic approach, quality of life

Biography

Mr Hooman Soleymani majd started his Obstetrics and Gynaecology career in London, before moving to Oxford where he completed his structured postgraduate training programme. During the course of training he obtained his membership of the Royal College of Obstetricians and Gynaecologists (MRCOG), which culminated in a Certificate of Completion of Training (CCT) in Obstetrics and Gynaecology. Mr. Soleymani majd completed a further three years of Sub-Specialty Training in Gynaecological Oncology at the Churchill Cancer Centre in Oxford. He is also a BSCCP accredited Colposcopist and trainer, as well as a member of the British Gynaecological Cancer Society (BGCS). He is an accomplished and experienced surgeon, performing numerous complex radical laparoscopic and open surgeries every year. He has a special interest in performing ultra-radical surgery for ovarian cancer; his skill set includes upper abdominal surgery, liver mobilisation and diaphragmatic reconstruction. Mr Soleymani majd also has a particular surgical interest in treating patients with Placenta Accreta Spectrum (PAS) and is a founding member of the OxPAT group. Further information available at : <https://www.placentaaccretaspectrum.com> Mr Soleymani Majd has active involvement in teaching registrars/fellows and medical students from Oxford University. He is part of an Oxford research group that has a special interest in new developments in surgical techniques in ultra-radical surgery for advanced ovarian cancer, he has published many papers and been invited to speak at a number of international congresses. He is on the editorial board of Gynecology and Pelvic Medicine (GPM) and the Journal of Obstetrics, Gynecology and Cancer Research (JOGCR). He is also a reviewer for BMJ case reports, European Journal of Gynaecology Oncology (EJGO) and Frontiers in Oncology. Mr Soleymani majd currently works as a Consultant in Gynaecological Oncology at the Churchill Hospital, Oxford, and has been in post since 2016.